Project measures / variables set:   CSNA03   dist_f30_cont_in

ID, description, units MPD:90328   dist_f30_cont_in   distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]  
Measures • day:    • 1    • 2    • 3    • 5    • 7    • 9    • 11    • 12    • 19
Data set, strains CSNA03   inbred w/CC8   9 strains     sex: both     age: 8-14wks
Procedure open field test
Comparisontimecourse, same cohort
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options

CSNA03 - distance traveled, first 30 min (pre-injection), on successive days, saline group, founders



  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary          "within" = Within error     "between" = Between Error (Animal ID)

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
within   day 8 307917524.713 38489690.5891 6.0947 < 0.0001
within   day:sex 8 118507896.4359 14813487.0545 2.3457 0.0171
within   day:strain 64 602316601.7688 9411196.9026 1.4902 0.0095
within   day:sex:strain 64 408192167.0462 6378002.6101 1.0099 0.4578
within   Residuals 792 5001712695.1823 6315293.807
between   sex 1 931046343.5385 931046343.5385 11.8897 0.0008
between   strain 8 17018121837.2981 2127265229.6623 27.1657 < 0.0001
between   sex:strain 8 906551126.4974 113318890.8122 1.4471 0.1866
between   Residuals 99 7752408356.5251 78307155.1164

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDTreatmentMeasure / Variable Description PanelStrains
tested		SexAge
CSNA03 90328 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 1  dist_f30_cont_in_d1 inbred w/CC8 9 both 8-14wks
CSNA03 90334 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 2  dist_f30_cont_in_d2 inbred w/CC8 9 both 8-14wks
CSNA03 90340 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 3  dist_f30_cont_in_d3 inbred w/CC8 9 both 8-14wks
CSNA03 90346 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 5  dist_f30_cont_in_d5 inbred w/CC8 9 both 8-14wks
CSNA03 90352 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 7  dist_f30_cont_in_d7 inbred w/CC8 9 both 8-14wks
CSNA03 90358 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 9  dist_f30_cont_in_d9 inbred w/CC8 9 both 8-14wks
CSNA03 90364 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 11  dist_f30_cont_in_d11 inbred w/CC8 9 both 8-14wks
CSNA03 90370 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 12  dist_f30_cont_in_d12 inbred w/CC8 9 both 8-14wks
CSNA03 90376 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, founders   [cm]   day 19  dist_f30_cont_in_d19 inbred w/CC8 9 both 8-14wks



  •   Or, add these measures to your collection.
       
  •     no folder
  •     put them in new folder